Funding for this research was provided by:
Centers for Disease Control and Prevention (5U01GH000048)
United States Agency for International Development (GHN-T-00-06-00001-00)
Received: 13 February 2019
Accepted: 23 July 2019
First Online: 29 July 2019
Ethics approval and consent to participate
: The study protocol and informed consent and assent forms were approved by the KEMRI Scientific and Ethics Review Unit (KEMRI protocol #2380). The CDC institutional review board relied on the KEMRI Scientific and Ethics Review Unit for approval. The Kenya Pharmacy and Poisons Board approved the protocol and importation of dihydroartemisinin-piperaquine (Eurartesim<sup>®</sup>, Sigman-Tau, Pomezia, Italy) for the study.
: Consent for publication was received from both KEMRI and CDC. The findings and conclusions in this manuscript are those of the authors and do not necessarily represent the official position of the United States Centers for Disease Control and Prevention or the Department of Health and Human Services. The paper is published with the permission of the Director, KEMRI, and the CDC.
: The authors declare that they have no competing interests.